Mumbai, Dec. 6 -- On 2 December, the Delhi high court allowed domestic drugmaker Dr Reddy's Laboratories Ltd to manufacture the blockbuster weight-loss injection semaglutide, for which global pharma giant Novo Nordisk holds the patent in India.

While Dr Reddy's can't sell the drug domestically until Novo's patent expires in March 2026, it can export it to countries where the Danish drugmaker does not have patent protection.

Given the order has significant implications for India's domestic pharma landscape, dotted with patent litigations between the country's generic players and innovators, Mint explains how Indian courts rule on complex patent disputes.

In May 2025, Novo Nordisk filed a patent-infringement suit against Dr Reddy's and c...